Home | Publications | Research (R&D) | Pipeline place holder
place holder place holder

Pipeline

ExonHit Therapeutics SA Product Pipeline Analysis


Publication Date   August 2008
Publisher   Global Markets Direct
Product Type   Report
Pages   27
ISBN Number   not applicable
Product Code   GMD628
Ask a question about this product?

Price £505.00

approximately: $753 | €602

Summary


This report is an insightful source for data, analysis and strategic insights into a ExonHit Therapeutics SA's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content


  • 1.1 List Of Tables
  • 1.2 List of Figures
  • 2 Company Overview
  • 2.1 Key Information
  • 2.2 Industry Outlook - In Vitro Diagnostics
  • 3 Major Products and Services
  • 3.1 Overview
  • 4 Competitors
  • 5 Key Employees
  • 6 Locations And Subsidiaries
  • 6.1 Head Office
  • 6.2 Other Locations & Subsidiaries
  • 7 Recent Developments
  • 7.1 Corporate Communications
    • 7.1.1 Apr 30, 2008: ExonHit Announces Board Changes
    • 7.1.2 Mar 31, 2008: ExonHit Appoints New Management Board
  • 7.2 Product News
    • 7.2.1 Jan 09, 2008: EXONHIT AND BIOMERIEUX AMEND THEIR STRATEGIC PARTNERSHIP
    • 7.2.2 Dec 20, 2007: Exonhit Gets Regulatory Approval To Initiate A Phase 2 Clinical Trial For EHT 0202 In Alzheimer's Disease
    • 7.2.3 Nov 08, 2007: Exonhit Completes A Prototype To Detect Alzheimer's Disease From Blood
    • 7.2.4 Jun 07, 2007: In 2009 Exonhit Aims To Ask For Market Clearance In Europe For A Blood Diagnostic Test For Alzheimer's Disease
  • 7.3 Product Approvals
    • 7.3.1 Dec 20, 2007: Exonhit Gets Regulatory Approval To Initiate A Phase 2 Clinical Trial For EHT 0202 In Alzheimer's Disease
  • 8 ExonHit Therapeutics SA Pipeline Products
  • 8.1 ExonHit Therapeutics SA Product Pipeline Analysis
    • 8.1.1 ExonHit Therapeutics SA Pipeline Products By Equipment Type
    • 8.1.2 ExonHit Therapeutics SA Pipeline Products By Development Stage
    • 8.1.3 ExonHit Therapeutics SA Pipeline Products By Therapy Area
    • 8.1.4 ExonHit Therapeutics SA Pipeline Products By News Summary
  • 8.2 EHT Dx 21
    • 8.2.1 Product Description
    • 8.2.2 Product Status
  • 8.3 EHT Dx 31
    • 8.3.1 Product Description
    • 8.3.2 Product Status
  • 8.4 EHT Dx 11
    • 8.4.1 Product Description
    • 8.4.2 Product Status
  • 8.5 EHT Dx 12
    • 8.5.1 Product Description
    • 8.5.2 Product Status
  • 8.6 EHT Dx13
    • 8.6.1 Product Description
    • 8.6.2 Product Status
  • 8.7 Diagnostic Test for Alzheimer's Disease
    • 8.7.1 Product Description
    • 8.7.2 Product Status
    • 8.7.3 Product Milestone
    • 8.7.4 Product Patent Details
  • 9 Appendix
  • 9.1 Methodology
    • 9.1.1 Coverage
    • 9.1.2 Secondary Research
    • 9.1.3 Primary Research
    • 9.1.4 Expert Panel Validation
  • 9.2 Contact Us
  • 9.3 About Global Markets Direct
  • 9.4 Disclaimer
  • 1 List of Tables
  • Table 1: ExonHit Therapeutics SA,Key Facts
  • Table 2: ExonHit Therapeutics SA, Key Employees,
  • Table 3: ExonHit Therapeutics SA, Subsidiaries
  • Table 4: ExonHit Therapeutics SA Pipeline Products by Equipment Type
  • Table 5: ExonHit Therapeutics SA Pipeline Products By Development Stage
  • Table 6: ExonHit Therapeutics SA Pipeline Products By Therapy Area
  • Table 7: ExonHit Therapeutics SA Pipeline Products By News Summaries
  • 1.2 List of Figures
  • Figure 1: ExonHit Therapeutics SA Pipeline Products By Equipment Type
  • Figure 2: ExonHit Therapeutics SA Pipeline Products By Equipment Type
  • Figure 3: ExonHit Therapeutics SA Pipeline Products By Development Stage
  • Figure 4: ExonHit Therapeutics SA Pipeline Products By News Summary
  • Figure 5: Global Markets Direct Methodology